Podcast 13 Oct 2023 Beyond Biotech podcast 67 – natural killer cells …trials. In August, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoimmune disease. AlloNK… October 13, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2017 CRISPR Does it Again! Gene Editing Tool Identifies a New Leukemia Target Researchers from the Wellcome Trust Sanger Institute have reported that a new target for the treatment of leukemia has been found. A new drug target for acute myeloid leukemia (AML)… December 6, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jul 2020 Swiss Company Raises €23M to Smash Cancer with Bacteria …to engulf the bacteria for the therapy to take effect, but T3 Pharma’s bacteria stay outside of the cell and can target many different types of cells. Image from Shutterstock… July 24, 2020 - 2 minutesmins - By Antara Mazumdar Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Gene activity could help identify risk of kidney cancer spreading …in recent years become an important treatment for patients with clear cell kidney cancer. But it is common for the cancer cells to develop resistance to the treatment, which may… October 17, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Research discovery may help diagnose and treat cancer and brain disorders …study not only sheds light on the development of one of the most important organs in our body – the brain – but it also shows how the same protein… August 10, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2020 Adaptimmune to Take Off-The-Shelf CAR-T to Phase I with Astellas …expressed by cancer cells and co-develop donor T-cell therapies that could tackle solid tumors expressing these molecules. The candidate T-cell therapies will consist of T-cells expressing engineered cancer-hunting proteins such… January 15, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 31 Dec 2018 European Biotech’s Biggest News of 2018 …to get FDA approval in 2019. Another diabetes treatment entered the clinic in April, but this time, it was cheesy. The Belgian company ActoBio Therapeutics hopes to treat type 1… December 31, 2018 - 12 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2017 Anti-Parasite Drug May Help to Treat Prostate Cancer, Say Norwegian Scientists …Bergen have been testing hundreds of drugs to see how they affect cancer cells. They have now found a drug taken to treat intestinal parasites, Giardia and tapeworms, which acts… November 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 23 Jan 2017 “Senior Staff Snobbery separates Academia from the Biotech Industry” …is that most academics are only interested in treating the patients for publications. Moreover, they try very experimental therapies without reliable animal models: these studies are the worst ‘first-in-man’ trials… January 23, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Oct 2025 Five latest advancements in Tourette’s syndrome research …children and teens are trained to monitor their tics and become aware of and overcome the urge to tic – there is a need for wider therapeutic approaches. This year witnessed a prospective treatment on the horizon as… October 20, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Sponsored by VALIDOGEN 4 Nov 2025 Rethinking protein production: Why Pichia pastoris is gaining ground in biotech …a cornerstone of the toolbox. Dib elaborates that their AOX1-derived promoter variants have different strengths and characteristics. This allows them to fine-tune promoter activity to match the specific requirements of… November 4, 2025 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Expert Advice 7 Sep 2019 Why Being in a New Field From the Start Can Pay Off in the Long Run …say 2006, even 2007 – and talking to them about immunology or immuno-oncology or T-cells. The typical answer was, ‘We don’t believe in that. These are T-cells. We don’t think… September 7, 2019 - 12 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email